HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
13.94
+0.46 (3.41%)
At close: Oct 15, 2026, 4:00 PM EDT
14.00
+0.06 (0.43%)
After-hours: Oct 15, 2026, 4:15 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,790 employees as of June 30, 2026.
Employees
1,790
Change
n/a
Growth
n/a
Revenue / Employee
$306,772
Profits / Employee
$9,991
Market Cap
2.49B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,790 | - | - |
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Alvotech | 1,279 |
| Prestige Consumer Healthcare | 890 |
| Indivior Pharmaceuticals | 838 |
| Supernus Pharmaceuticals | 778 |
| BioCryst Pharmaceuticals | 435 |
HCM News
- 6 days ago - HUTCHMED (China) Ltd (HCM) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 78/100 - GuruFocus
- 7 days ago - HUTCHMED (China) Ltd (HCM) Shares Fall 4.3% -- What GF Score of 77 Tells Investors - GuruFocus
- 15 days ago - HUTCHMED (China) Ltd (HCM) Shares Surge 3.4% -- What GF Score of 79 Tells Investors - GuruFocus
- 17 days ago - HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer - Nasdaq
- 17 days ago - AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination - Reuters
- 17 days ago - Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC - TheFly
- 17 days ago - HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewsWire
- 18 days ago - Hutchmed (HCM) Launches Phase Ia Trial for HMPL-A830 in Advanced Solid Tumors - GuruFocus